Literature DB >> 10665265

Neuropsychiatry of Huntington's disease and other basal ganglia disorders.

A Rosenblatt1, I Leroi.   

Abstract

Degenerative diseases of the basal ganglia, such as Huntington's disease (HD), Parkinson's disease, and Wilson's disease, are characterized by motor, cognitive, and psychiatric manifestations. HD, in particular, can be considered a paradigmatic neuropsychiatric disorder that has all three components of the "Triadic Syndromes": dyskinesia, dementia, and depression. The authors examine the phenomenology, prevalence, and management of psychiatric disturbances occurring in diseases of the basal ganglia. They address psychiatric conditions such as depression, mania, psychosis, obsessive-compulsive disorders, aggression, irritability, apathy, sexual disorders, and delirium, discussing subtleties of diagnosis, and making reference to more unusual disorders of the basal ganglia, such as postencephalitic parkinsonism and Fahr's disease.

Entities:  

Mesh:

Year:  2000        PMID: 10665265     DOI: 10.1016/S0033-3182(00)71170-4

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  39 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 2.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

Review 3.  Sexuality in Huntington's disease.

Authors:  Eva Z Schmidt; Raphael M Bonelli
Journal:  Wien Med Wochenschr       Date:  2008

4.  Understanding the psychiatric prodrome of Huntington disease.

Authors:  Adam Rosenblatt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

Review 5.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

6.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

Review 7.  Young-onset dementia epidemiology applied to neuropsychiatry practice.

Authors:  Bhargavi Devineni; Chiadi U Onyike
Journal:  Psychiatr Clin North Am       Date:  2015-03-26

Review 8.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

9.  Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions.

Authors:  Shunichiro Shinagawa; Georges Naasan; Anna M Karydas; Giovanni Coppola; Mochtar Pribadi; William W Seeley; John Q Trojanowski; Bruce L Miller; Lea T Grinberg
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-10-23       Impact factor: 2.680

Review 10.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.